Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FAM151B-DT is a cytoplasmic long non-coding RNA located on chromosome 5q12.1, transcribed from the negative strand in divergent orientation. It is widely expressed in the central nervous system, especially in neurons. This lncRNA modulates autophagic flux by acting as a scaffold or mediator for chaperone proteins like HSC70, facilitating the lysosomal degradation of proteins prone to aggregation, specifically tau and α-synuclein. Silencing FAM151B-DT blocks autophagy, leading to pathologic protein accumulation, while increasing its expression promotes autophagic clearance and reduces neurotoxic protein aggregates. FAM151B-DT is altered in stem cell models of neurodegeneration and in human brains afflicted with Alzheimer’s disease, Parkinson’s disease, FTLD-tau, and PSP. This molecular profile and functional data designate FAM151B-DT as a novel and promising therapeutic target for neurodegenerative diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FAM151B divergent transcript (FAM151B-DT).